Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 5kWORD 29k
24 August 2018
Answer given by Mr Andriukaitis on behalf of the European Commission
Question reference: P-003774/2018

The Commission is very much aware of the necessity for the European Medicines Agency (EMA) to deliver its public and animal health activities continuously to ensure that medicinal products (for human and veterinary use) authorised in the EU meet the criteria of safety, efficacy and quality. As a member on its Management Board, the Commission closely follows the Agency's proposed measures to mitigate the related business continuity risks arising from the relocation of EMA to Amsterdam.

In the framework of the 2019 budgetary procedure, EMA requested 40 additional contract agents for a temporary period. This request and the supporting information provided by EMA were particularly carefully analysed by the Commission services. The request and information provided by EMA were judged as not being sufficiently documented to support such an increase in staff, even for a temporary period, taking into account also the relatively large size of the Agency.

It should be noted that any requests for staff increase need to be very well substantiated via the budgetary procedure.

The Commission remains in close contact with the Agency as regards the departure of key staff and its impact on the capacity of EMA to deliver on its high priority activities.

Last updated: 27 August 2018Legal notice - Privacy policy